Unicycive Therapeutics, Inc. — News

- Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor

globenewswire.com - 2026-08-12 07:19:00

BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Block and Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive Therapeutics, Inc.

globenewswire.com - 2026-07-13 14:05:18

BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.

globenewswire.com - 2026-07-13 14:05:00

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

globenewswire.com - 2026-07-10 20:00:00

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter (“CRL”) reg.

businesswire.com - 2026-07-08 20:00:00

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON UNICYCIVE THERAPEUTICS, INC. (UNCY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

businesswire.com - 2026-07-08 12:34:00

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UNICYCIVE THERAPEUTICS, INC. (UNCY), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your.

businesswire.com - 2026-07-08 09:00:00

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON UNICYCIVE THERAPEUTICS, INC. (UNCY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On June 30, 2026, Unicycive disclosed that the FD.

businesswire.com - 2026-07-07 18:28:00

NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened?

globenewswire.com - 2026-07-06 20:00:00

Boston, Massachusetts--(Newsfile Corp. - July 6, 2026) - Block & Leviton is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.

newsfilecorp.com - 2026-07-06 08:42:00

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options

globenewswire.com - 2026-07-02 13:14:00

Boston, Massachusetts--(Newsfile Corp. - July 2, 2026) - Block & Leviton is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.

newsfilecorp.com - 2026-07-02 08:45:00

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Lett.

businesswire.com - 2026-07-01 19:00:00

Block & Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: $UNCY) for possible securities law violations. Investors should contact the firm.

globenewswire.com - 2026-07-01 10:43:00

SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.

globenewswire.com - 2026-06-30 12:51:00

-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor -- -- FDA inspection of third-party facility did not occur during the NDA resubmission review --

globenewswire.com - 2026-06-30 07:05:00

Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved patient adherence, with a PDUFA date set for June 29, 2026. Key risks include payer acceptance of premium pricing, patent term uncertainty, and lack of outcomes data supporting improved adherence.

seekingalpha.com - 2026-05-21 02:54:09